Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ELVN vs TLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–3 Matrix Metrics)

TLX Overall Winner 6-Pillar Tally: ELVN 1 – 5 TLX Matrix Metrics: ELVN 3 – 6 TLX

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas TLX carries 55.2/100 (HOLD) at $8.98 (N/M Forward P/E, 6.2% operating margin).

  • Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile TLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ELVN vs TLX
ELVN NASDAQ
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 60% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.3 · SMA20: $45.78 · SMA50: $46.20
TLX NASDAQ Head-to-Head Winner
Telix Pharmaceuticals Limited American Depositary Shares
Pharmaceutical Preparations
$8.98
-2.65% 1D
Market Cap $3.2B
TTM Revenue $891M
Forward P/E N/M
Beta / 30D Vol 0.84β · 62% Vol
Unified Composite Score
55.2 / 100 HOLD
Tech 74.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.7%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $9.46 · SMA50: $10.61

6-Pillar Scorecard Institutional Category Breakdown (ELVN 1 – 5 TLX)

Columns: Metric · ELVN · TLX
1. Valuation Multiples TLX
Forward P/E N/M N/M
Trailing P/E N/M 93.6x
PEG Ratio N/M N/M
EV / Revenue N/M 3.6x
2. Growth & Scale TLX
Revenue Growth (YoY) +0.0% +22.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $891M
Market Cap $3.6B $3.2B
3. Profitability & Quality TLX
Gross Margin N/A 47.6%
Operating Margin 0.0% 6.2%
Net Profit Margin 0.0% 3.8%
Return on Equity (ROE) -16.8% 7.4%
4. Balance Sheet & Cash Flow TLX
Cash Generation (TTM) -$66M $70M EBITDA
Cash Flow Margin N/A 7.8% EBITDA Mgn
Net Cash / Leverage $150M Net Cash $1.44 Book/Sh · 7.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ELVN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 46.9% (5th %ile) N/A (N/A)
Put/Call OI Skew 1.67x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat TLX
OpEx & R&D Intensity N/A 41.4% of Rev ($369M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ELVN (3) vs TLX (6)
Institutional Metric ELVN TLX Criterion Row Edge
Market Capitalization
Scale
$3.6B $3.2B Larger Scale ELVN
Trailing P/E Ratio
Valuation
N/M 93.6x Lower Multiple TLX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +22.3% Higher Growth TLX
Operating Margin (TTM)
Profitability
0.0% 6.2% Higher Margin TLX
Net Profit Margin
Profitability
0.0% 3.8% Higher Margin TLX
Return on Equity (ROE)
Capital Efficiency
-16.8% 7.4% Higher ROE TLX
52-Week Range Position
Momentum
69% ($15–$62) 40% ($6–$13) Stronger Trend ELVN
Beta / 30D Volatility
Risk Regime
0.96β · 60% Vol 0.84β · 62% Vol Lower Realized Risk ELVN
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 55.2 / 100 (HOLD) Higher Composite TLX
Trailing 12M Revenue (USD)
Operating Scale
N/A $891M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 47.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($150M Net Cash) $70M EBITDA ($1.44 Book/Sh · 7.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELVN +43.33 pp
ELVN: +27.38% · TLX: -15.95%
3M Horizon ELVN +3.51 pp
ELVN: -20.86% · TLX: -24.37%
6M Horizon ELVN +32.56 pp
ELVN: +19.96% · TLX: -12.6%
1Y Horizon ELVN +140.05 pp
ELVN: +134.53% · TLX: -5.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs TLX. Trailing 12-month operating profitability (ELVN 0.0% vs TLX 6.2%) and valuation multiples (ELVN N/M vs TLX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ELVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-16.8% · N/M
TLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$891M
Gross Margin47.6%
Op. Margin6.2%
ROE / Fwd P/E7.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ELVN CONSOLIDATION
59d in phase · OBV NEUTRAL
Current IV 46.9%
IV Percentile 5th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ELVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TLX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment 41.4% of Rev ($369M)
90D Engineering Disclosures 0 Published

Investor FAQ ELVN vs TLX Key Questions & Quantitative Answers

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas TLX carries 55.2/100 (HOLD) at $8.98 (N/M Forward P/E, 6.2% operating margin). Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile TLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLX leads the Growth & Scale pillar: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TLX at +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus $891M for TLX. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus 41.4% of Rev ($369M) (0 disclosures) for TLX.

TLX screens cheaper on headline valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus TLX (7.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk). By comparison, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Telix Pharmaceuticals Limited American Depositary Shares (TLX) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.